Subsidiary Formed to Market H Pylori Test

A new subsidiary is being established by Orexo AB (Uppsala, Sweden) to commercialize the company's breath test for Helicobactor pylori.

The test is based on Orexo's patented technology for fast-dissolving tablets. These tablets offer greater reliability, lower dose, shorter test time, and lower cost. The company has signed distribution and marketing agreements for the test, called Diabact UBT, with companies in Finland, Hong Kong, Ireland, the United Kingdom, and Sweden.

Orexo points out that by diagnosing H pylori infection and treating it with antibiotics, stomach ulcers can be effectively cured. In recent years, it has also been found that early treatment of H pylori infection can reduce the risk of developing certain forms of stomach cancer. Diabact UBT is the company's first commercialized product.

"Diabact UBT has significant market potential. To successfully capitalize on this potential, we are forming a subsidiary with the objective to create a strong position for the test in existing and new markets,” said Zsolt Lavotha, president and CEO of Orexo. "This subsidiary shall be provided with autonomy to actively in-license products and/or enhance its operation based on strategic transactions.”




Related Links:
Orexo AB